Search research articles
Contact Us
Filters
Showing results (191-200 of 234) with videos related to
Page
of 24
Sort By:
Molecular Cancer Research : MCR
|
May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer
Erolcan Sayar, Helen M Richards, Roman Gulati, et al.
NPJ Precision Oncology
|
May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
Azra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2019
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Himisha Beltran, Andrew Hruszkewycz, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Cancer Research Communications
|
August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Hyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
The Journal of Urology
|
January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
Natalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
European Urology Focus
|
July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study
Andrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
Page
of 24
Search research articles
Search
Showing results (191-200 of 234) with videos related to
Sort By:
Page
of 24
Molecular Cancer Research : MCR
|
May 26, 2026
Integrative Surface Antigen Profiling of KLK2 and STEAP1 in Advanced Prostate Cancer
Erolcan Sayar, Helen M Richards, Roman Gulati, et al.
NPJ Precision Oncology
|
May 17, 2024
Assessment of TROP2, CEACAM5 and DLL3 in metastatic prostate cancer: Expression landscape and molecular correlates
Azra Ajkunic, Erolcan Sayar, Martine P Roudier, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 1, 2019
The Role of Lineage Plasticity in Prostate Cancer Therapy Resistance
Himisha Beltran, Andrew Hruszkewycz, Howard I Scher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 8, 2023
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial
Emmanuel S Antonarakis, Se Hoon Park, Jeffrey C Goh, et al.
Nature Medicine
|
January 17, 2025
Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial
Alicia F C Okines, Giuseppe Curigliano, Nobumasa Mizuno, et al.
Cancer Research Communications
|
August 6, 2025
Patterns of HER2 Expression in Metastatic Prostate and Urothelial Cancers: Implications for HER2-Targeted Therapies
Hyun Jung Lee, Roman Gulati, Erolcan Sayar, et al.
European Urology
|
March 21, 2014
Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)
Dana E Rathkopf, Matthew R Smith, Johann S de Bono, et al.
Clinical Genitourinary Cancer
|
January 11, 2025
Clinical Outcomes With Immune Checkpoint Inhibitors in Patients With FGFR2/3, MTAP or ERBB2 Genomic Alterations in Advanced Urothelial Carcinoma
Rafee Talukder, Dimitra Rafailia Bakaloudi, Dimitrios Makrakis, et al.
The Journal of Urology
|
January 24, 2020
Histological Subtypes and Response to PD-1/PD-L1 Blockade in Advanced Urothelial Cancer: A Retrospective Study
Natalie J Miller, Ali Raza Khaki, Leonidas N Diamantopoulos, et al.
European Urology Focus
|
July 30, 2017
Robot-assisted Versus Open Radical Cystectomy in Patients Receiving Perioperative Chemotherapy for Muscle-invasive Bladder Cancer: The Oncologist's Perspective from a Multicentre Study
Andrea Necchi, Gregory R Pond, Marc C Smaldone, et al.
Page
of 24